| ID | 1206 |
| Name of the vaccine | Spirolept |
| Microbe | Bacteria |
| Disease name | Leptospirosis |
| Name of bacteria | Leptospira genus |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 18 to 65 years |
| Description of the vaccine | Killed whole-cell Leptospiral vaccine. |
| Name of the manufacturer | Imaxio |
| Name of the manufacturing country | France |
| Year of manufacture | 2018 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Four to eight doses.
Usual dose - Two injections 15 days apart, followed by a booster 4 to 6 months later. |
| Mechanism of action | Anti-leptospira IgG antibody. |
| Route of administration | Subcutaneous |
| Indications | Prevention of leptospirosis caused by the serogroup Icterohaemorrhagiae and Copenhageni. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Pain or swelling, fever, headache, malaise, dizziness, nausea, muscle pain, tingling in extremity, rash, hives, fatigue. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | Yes (through the urine of infected animals) |
| PubMed identifier | NA |
| Clinical trial number | NCT03497572 |
| Reference | https://www.vidal.fr/medicaments/gammes/spirolept-13536.html |
| Other name | NA |
| Additional Links | NA
|